Cargando…

Efficacy and safety of potent P2Y12 inhibitors vs. clopidogrel in elderly patients with acute coronary syndrome

Detalles Bibliográficos
Autores principales:	Luo, Li-Man, Pang, Zhan-Qi, Fu, Meng-Lu, Li, Yuan-Yuan, Tu, Ling, Xu, Xi-Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722603/ https://www.ncbi.nlm.nih.gov/pubmed/32991367 http://dx.doi.org/10.1097/CM9.0000000000001119

Ejemplares similares

Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis
por: Pang, Jun, et al.
Publicado: (2019)

Novel Oral P2Y12 Inhibitor Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndrome: Evidence Based on 6 Studies
por: Jia, Min, et al.
Publicado: (2015)

Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
por: Ng, Andrew Kei-Yan, et al.
Publicado: (2022)

Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Xi, Ziwei, et al.
Publicado: (2021)

Meta-Analysis Comparing Potent Oral P2Y(12) Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
por: Casula, Matteo, et al.
Publicado: (2020)

Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome
por: Wang, Huidong, et al.
Publicado: (2016)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Chen, Po-Wei, et al.
Publicado: (2020)

Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Li, Jianan, et al.
Publicado: (2021)

MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
por: Zhou, Yong, et al.
Publicado: (2022)

Safety and efficacy of the Expressman Extension System for complex coronary lesions during percutaneous coronary intervention
por: Ma, Yanzhuo, et al.
Publicado: (2023)

Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention: a real-world study
por: Wang, Ping, et al.
Publicado: (2022)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
por: Selvarajah, Abi, et al.
Publicado: (2021)

Comparison of Safety and Efficacy Between Clopidogrel and Ticagrelor in Elderly Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
por: Zhao, Xiangkai, et al.
Publicado: (2021)

CRISPR-Cas12a-assisted nucleic acid detection
por: Li, Shi-Yuan, et al.
Publicado: (2018)

Ticagrelor vs. clopidogrel for coronary microvascular dysfunction in patients with STEMI: a meta-analysis of randomized controlled trials
por: Li, Yike, et al.
Publicado: (2023)

miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome
por: Mo, Zhen-Zhen, et al.
Publicado: (2023)

Letter to the Editor: How Should We Treat High-risk Patients in the Chronic Phase Following PCI: Clopidogrel or Prolonged DAPT?
por: Wang, Hao-Yu, et al.
Publicado: (2021)

Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction
por: Yeh, Jong-Shiuan, et al.
Publicado: (2023)

Stratum corneum hydration inversely correlates with certain serum cytokine levels in the elderly, possibly contributing to inflammaging
por: Yang, Bin, et al.
Publicado: (2023)

Influence of GAS5/MicroRNA‐223‐3p/P2Y12 Axis on Clopidogrel Response in Coronary Artery Disease
por: Liu, Yan‐Ling, et al.
Publicado: (2021)

Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST‐Segment–Elevation Myocardial Infarctions
por: Schmucker, Johannes, et al.
Publicado: (2019)

An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease
por: Iskandar, Nicholas P, et al.
Publicado: (2022)

Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
por: Song, Kai, et al.
Publicado: (2022)

Efficacy and safety of low dose aspirin plus clopidogrel in the treatment of elderly patients with symptomatic intracranial artery stenosis
por: Song, Hai-xia, et al.
Publicado: (2023)

Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy
por: Liu, Ping-Yen, et al.
Publicado: (2021)

The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
por: Luo, Liman, et al.
Publicado: (2019)

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Wang, He-Yang, et al.
Publicado: (2018)

Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial
por: Zhou, Tienan, et al.
Publicado: (2023)

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
por: Zhang, Yan-Jiao, et al.
Publicado: (2022)

Thrombotic risk stratification of coronary aneurysms in Kawasaki disease patients: the study of morphology and hemodynamics
por: Cao, Haoyao, et al.
Publicado: (2022)

Impact of Ticagrelor vs. Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention After Risk Stratification With the CHA(2)DS(2)-VASc Score
por: Na, Kun, et al.
Publicado: (2022)

Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry
por: Zhang, Yunnan, et al.
Publicado: (2022)

Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome
por: van den Broek, Wout W A, et al.
Publicado: (2022)

Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous Coronary Intervention: Results From the HOST-EXAM Study
por: Hwang, Doyeon, et al.
Publicado: (2023)

Prevalence and Safety of Prescribing PPIs with Clopidogrel in Palestine
por: Abukhalil, Abdallah Damin, et al.
Publicado: (2023)

Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China
por: Guo, Yong-zheng, et al.
Publicado: (2020)

Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors, Clopidogrel, or Both?
por: Silva, Matthew A, et al.
Publicado: (2006)

Determinants to optimize response to clopidogrel in acute coronary syndrome
por: Giusti, Betti, et al.
Publicado: (2010)

Use of edaravone to decrease perioperative neurocognitive disorders in elderly patients with hip replacement
por: Yuan, Yujing, et al.
Publicado: (2023)

Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
por: Zheng, Wei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3idvjnr1qeg2u1l6jc26e909is